Morningstar Investment Management LLC Has $1.98 Million Stake in Prestige Consumer Healthcare Inc. $PBH

Morningstar Investment Management LLC raised its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 118.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 33,410 shares of the company’s stock after acquiring an additional 18,082 shares during the quarter. Morningstar Investment Management LLC owned approximately 0.07% of Prestige Consumer Healthcare worth $1,980,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in PBH. UMB Bank n.a. increased its position in shares of Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares in the last quarter. Bayforest Capital Ltd acquired a new position in Prestige Consumer Healthcare in the fourth quarter valued at about $29,000. Torren Management LLC bought a new stake in Prestige Consumer Healthcare during the fourth quarter worth about $35,000. Caitong International Asset Management Co. Ltd grew its stake in Prestige Consumer Healthcare by 69.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock worth $35,000 after buying an additional 236 shares during the last quarter. Finally, Danske Bank A S acquired a new stake in shares of Prestige Consumer Healthcare during the third quarter worth approximately $37,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insider Activity

In other news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the sale, the vice president directly owned 42,820 shares in the company, valued at $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on PBH shares. Weiss Ratings lowered Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Finally, Canaccord Genuity Group dropped their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Stock Performance

PBH stock opened at $49.67 on Friday. Prestige Consumer Healthcare Inc. has a 1-year low of $42.62 and a 1-year high of $77.03. The business’s 50-day moving average price is $47.94 and its two-hundred day moving average price is $56.91. The firm has a market cap of $2.35 billion, a PE ratio of 12.70, a P/E/G ratio of 1.60 and a beta of 0.35. The company has a current ratio of 3.57, a quick ratio of 2.25 and a debt-to-equity ratio of 0.54.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The business had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. During the same period in the prior year, the business earned $1.32 EPS. The company’s revenue for the quarter was down 5.0% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).